Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

[Q]: Paragraph: A panel of Food and Drug Administration advisers voted unanimously in favor of Amgen’s version of AbbVie’s Humira, a biotech drug that raked in nearly $15 billion last year, according to IMS Health. While not binding, the recommendation likely paves the way for FDA approval of the knockoff drug. For years, biotech drugs faced no competition because there was no regulatory way to approve copycat versions, even after patents had expired. If approved, Amgen’s drug would join a new wave of so-called biosimilars, which have the potential to generate billions in savings for U.S. insurers, doctors and patients. But it could take years for those savings to arrive. Evercore ISI analyst Mark Schoenebaum says the earliest Amgen could launch its product would be March 2017, though that would risk infringing patents which Abbvie says protect its drug until at least 2022. Wall Street analysts expect the patent issue to be fought in court, and then for Amgen’s drug to launch sometime between 2018 and 2022. First approved in 2002, Humira has long been among the most profitable drugs in the world. It accounted for 60 percent of Abbvie’s total revenue last year. The injectable drug, which blocks chemicals linked to inflammation, is approved for multiple uses, including rheumatoid arthritis, Crohn’s disease and psoriasis. Thousand Oaks, Calif-based Amgen is seeking FDA approval to market its version, known only as ABP 501, for seven diseases. Amgen is itself a biotech powerhouse, and it too has medications facing competition from cheaper versions. The company is working to hedge those loses by developing lower-cost versions of competitors’ drugs. Biotech drugs are powerful, injected medicines produced in living cells that are typically much more expensive than traditional, chemical-based drugs. In 2015, six of the 10 top-selling medicines globally were biotech drugs, with more than $56 billion in combined sales. The FDA only approved the first lower-cost biotech drug last March, a Novartis version of the Amgen drug Neupogen. Pfizer won approval to market a second biosimilar in April, a version of Johnson & Johnson’s Remicade, but it is not yet for sale. Questions remain about just how much savings U.S. biosimilars will deliver. Novartis’ Zarxio sells for 15 percent less than the original Neupogen. Experts predict biosimilar discounts of 15 percent to 30 percent in the U.S. In Europe, where governments regulate prices, discounts are higher. Development of lower-cost anti-inflammatory drugs like Humira is considered pivotal in reducing U.S. spending on specialty drugs, which has doubled to $150 billion since 2010, according to IMS Health. On Wednesday, the same panel of FDA advisers will review a Novartis version of Enbrel, which is marketed by Amgen. Claim: Lower-cost biotech drug gets thumbs up from FDA panel.
[A]: The second-biggest selling drug in the world could get some cheaper competition in the U.S., after a federal panel endorsed an alternative version of the pricey medication used to treat rheumatoid arthritis and other inflammatory diseases.


[Q]: Paragraph: Health Ministry spokesman Kianush Jahanpur, speaking on  state television, said the death toll had risen by 92, while the total number of cases of infection reached 77,995. However, a report by the Iranian parliament’s research centre suggested that the coronavirus tolls might be almost twice as many as those announced by the health ministry. “The assessment is that the actual mortality which has not been accounted for is 0.8 times the official figures. The number of infected cases could be 8 to 10 times the official figures,” the report said. The report said that Iran’s official coronavirus figures were only based on the number of deaths in hospitals and those who had already tested positive for the coronavirus. “To narrow the gap between the officially announced figures and the estimated figures, it is necessary to improve the laboratory capacity of the country,” it said. Iranian health ministry officials have not commented on the report, which was published online. The government is worried that measures to limit public activities could wreck an economy which has already been battered by sanctions. On Saturday, low-risk business activities resumed across the country, including many shops, factories and workshops, with the exception of Tehran. They will re-open in the capital from Saturday. Health experts have criticised easing of the limitations, warning about the new wave of the disease. Deputy Health Minister Iraj Harirchi called on people to stay at home, saying: “We are expecting the epidemic to pick up in autumn”, state TV reported. On social media, Iranians posted pictures of busy streets, packed branches of banks and crowded buses in Tehran and other cities. Iran is the Middle Eastern country worst-affected by the COVID-19 respiratory disease and has one of the world’s highest death tolls. Claim: Iran coronavirus death toll up as official warns of autumn rise in cases.
[A]: Iran’s official coronavirus death toll rose to 4,869 on Thursday but a parliamentary report said the actual number could be much higher and a deputy minister warned the infection could spread further in autumn.


[Q]: Paragraph: Americans are living healthier and longer that ever before. The U.S. Census Bureau predicts boomers will turn 65 at a rate of 10,000 per day for the next decade, making them, along with centenarians, the fastest-growing segment of the population. More than 75 percent of seniors questioned in the poll on aging are optimistic, think the best is yet to come, and expect to have the same quality of life, or better, during their next decade. “The reason they are upbeat is because we have changed our definition of aging. People are working longer. They see people that are older being healthier,” said Donna Shalala, the president of the University of Miami and a former U.S. Secretary of Health and Human Services during the Clinton administration. Shalala, 71, who will discuss the results of the poll during a panel on successful aging in Miami on Wednesday, said people are buoyed by seeing their relatives living longer. “My mother is 100 years old. Why shouldn’t I be optimistic?” she added. The majority of 2,250 seniors, aged 60 or older, questioned in the telephone survey from the National Council on Aging, medical insurer UnitedHealthcare and the newspaper USA Today said they are confident they will be able to maintain their health and think they manage stress effectively. Although many seniors feel financially secure, nearly half of low- and middle-income seniors questioned in the poll are not confident they will be able to cover their expenses over the next five to 10 years. About a third of older Americans do not think they will be able to afford long-term care, according to the poll, and for 1 in 5 seniors, a major financial event would result in a fiscal crisis. Lower income seniors are also more likely to suffer from chronic illnesses and less likely to exercise. Seventy-two percent of people who make less than $30,000 a year said they live with a lingering health problem. Whether it is out of necessity, a sense of productivity, or the enjoyment of it, about 20 percent of seniors over 65 said they are still working either full- or part-time. “The market absolutely threw this generation off,” Shalala said about the impact of the recession. And just as many seniors are staying in the workplace longer, the vast majority want to “age in place,” or continue to live in their own home for the next decade. It could be a feasible option for most 60 somethings, but less than half of seniors in their 70s said they could live independently. The poll also showed that a lack of services in the community is a concern for seniors. More than 25 percent of people in their 60s were not confident there would be resources and facilities in their communities to allow them to live independently. “With appropriate preventive care and lifestyle changes, growing older doesn’t have to mean living with chronic disease and disability,” said Rhonda Randall, the chief medical officer at United Healthcare & Retirement. The poll was conducted between May 10 and June 6. The margin of error for the general population is +/-3.1 percent. Claim: Older Americans upbeat about aging, future: survey.
[A]:
Baby boomers are upbeat about aging and expect the next phase of their lives to be better than the last, but many are concerned about their financial future and long-term health costs, a survey released in Tuesday showed.